



## DSECT/DSEN Monthly Seminar Series

### “Active surveillance and pharmacogenomic biomarkers to optimize Hepatitis C treatment approaches in Canada”

Presented by **Dr. Bruce Carleton, PharmD**

*Professor, Faculties of Medicine (Paediatrics) and Pharmaceutical Sciences  
Director, Pharmaceutical Outcomes Programme, Children’s and Women’s Health Centre of BC  
Senior Clinician Scientist, Child & Family Research Institute*

**Thursday, Feb 26, 2015 at 3:00-4:00 p.m. EST**  
**Online webinar (GoToWebinar)**

**RSVP: <https://attendee.gotowebinar.com/register/30000000010754789>**

In this presentation Dr. Carleton will highlight a new approach to treating Chronic Hepatitis C (HCV) infection, a significant medical and economic burden in Canada. Approximately 250,000 Canadians have HCV and some patients develop sequelae, including cirrhosis or end stage liver disease. Historically, treatment has had a relatively low efficacy rate; approximately 30% of patients attaining the desired endpoint of sustained virological response (SVR) and a high prevalence of adverse drug reactions (ADRs). Newer treatments have much higher SVR rates, but heterogeneity in response is observed with all drugs; not all patients achieve adequate SVR, some experience relapse, and some still suffer from serious ADRs. Predictive pharmacogenomic biomarkers can be used to predict in whom SVR is most likely to occur and can help optimize treatment effectiveness. This can help patients, clinicians, and policy makers avoid the unnecessary cost and additional ADR risks that are likely to occur in some patients with some regimens, while also identifying those patients whose risk-benefit profile would clearly favour the use of more expensive therapeutic options.

#### Learning Objectives

At the conclusion of this session, participants will be able to:

- Describe how pharmacogenomic biomarker research can contribute to rapidly evolving therapeutic areas like HCV infection when costs are high.
- List the ways pharmacogenomic biomarker research can help understand the genetic factors involved in drug-induced harm when post market surveillance data is limited
- Discuss how predictive pharmacogenetic models can help patients, clinicians and policy makers better understand the risk and benefit profile of drug therapy

The **Drug Safety and Effectiveness Cross-Disciplinary Training (DSECT)** program and the **Drug Safety and Effectiveness Network (DSEN)** are presenting a monthly online seminar series for faculty, staff, trainees, decision-makers, and other stakeholders engaged in the field of drug safety and effectiveness.

**For more information, please visit [www.safeandeffectiverx.com](http://www.safeandeffectiverx.com) or contact:**

Lisa Dolovich  
DSECT Principal Investigator  
Email: [ldolovic@mcmaster.ca](mailto:ldolovic@mcmaster.ca)

Melissa Pirrie  
DSECT Program Coordinator  
Phone: (905) 525-9140 x27766  
E-mail: [pirrie@mcmaster.ca](mailto:pirrie@mcmaster.ca)